EVFM (Evofem Biosciences) Shares Buyback Ratio %: 0.00 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Evofem Biosciences Shares Buyback Ratio %?

Evofem Biosciences EVFM -1.30% Shares Buyback Ratio % is 0.00 as of Sep. 22, 2026. The stock has 5 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Evofem Biosciences's current shares buyback ratio was 0.00%.

Evofem Biosciences Shares Buyback Ratio % Related Terms

Evofem Biosciences Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Shares Buyback Ratio % Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -99.75 -1,036.29 -1,931.69 -466.56 -11.76

Evofem Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.68 -4.47 -2.20 -4.61 0.00

Evofem Biosciences Shares Buyback Ratio % Calculation

Evofem Biosciences's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(113.356354 - 126.685925) / 113.356354
=-11.76%

Evofem Biosciences's Shares Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2026 ) - Shares Outstanding (EOP) (A: Jun. 2026 )) / Shares Outstanding (EOP) (A: Mar. 2026 )
=(132.530081 - 132.530081) / 132.530081
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of 0.00 mean?
Evofem Biosciences (EVFM) has a Shares Buyback Ratio % of 0.00 as of Sep. 22, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Evofem Biosciences and its competitors.
Is Evofem Biosciences' Shares Buyback Ratio % too high?
Evofem Biosciences' current Shares Buyback Ratio % is 0.00.
How does Evofem Biosciences' Shares Buyback Ratio % compare to BZYR and ZVSA?
Evofem Biosciences' Shares Buyback Ratio % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current Shares Buyback Ratio % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 24% below its estimated fair value. The current Shares Buyback Ratio % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Shares Buyback Ratio % is 0.00 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.